Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497796 · ClinicalTrials.gov registry record · Phase 3
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
NCT00497796 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 307 participants.
The verdict
NCT00497796, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.
Interventions
- DRUG ganciclovir
- DRUG maribavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2007-07-23 |
| Est. Completion | 2009-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00497796
The ClinicalTrials.gov registry entry for NCT00497796 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ganciclovir is the first listed.
NCT00497796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00497796 about?
NCT00497796 is a clinical study titled "Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients". The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.
What is the current status of trial NCT00497796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2007-07-23. Estimated completion is 2009-09-14.
What interventions are being tested in trial NCT00497796?
The interventions under investigation include: ganciclovir (DRUG), maribavir (DRUG).
Who is sponsoring clinical trial NCT00497796?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.